Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | HTR1E | P28566 | 2/20 | 0.59 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | DRD1 | P21728 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5051927 | 1.00 | MEN1 (0.59) | MEN1KMT2AHTR1ES1PR3LMNA | |
| SCHEMBL14453320 | 1.00 | MEN1 (0.59) | MEN1KMT2AHTR1ES1PR3LMNA | |
| SCHEMBL14453324 | 1.00 | MEN1 (0.59) | MEN1KMT2AHTR1ES1PR3LMNA | |
| Water SCHEMBL28154809 | 0.98 | MEN1 (0.58) | MEN1KMT2AHTR1ES1PR3LMNA | |
| SCHEMBL4866289 | 0.98 | HTR1E (0.61) | MEN1KMT2AHTR1ES1PR3LMNA | |
| Hydrochloric Acid SCHEMBL5051899 | 0.96 | HTR1E (0.59) | MEN1KMT2AHTR1ES1PR3LMNA | |
| SCHEMBL5049598 | 0.95 | HTR1E (0.57) | MEN1KMT2AHTR1ES1PR3LMNA | |
| SCHEMBL4176732 | 0.91 | HTR1E (0.51) | MEN1KMT2AHTR1ES1PR3LMNA | |
| SCHEMBL22188704 | 0.91 | HTR1E (0.51) | MEN1KMT2AHTR1ES1PR3LMNA | |
| SCHEMBL14721053 | 0.86 | PTGES (0.50) | MEN1KMT2AHTR1ES1PR3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190680-A1 | Heteroaryl Amide Analogues | H. LUNDBECK A/S (DK) | 2012-07-26 | — | — | US | claimed |
| EP-2185560-A1 | HETEROARYL AMIDE ANALOGUES | H. Lundbeck A/S (DK) | 2010-05-19 | — | — | EP | claimed |
| US-20090233920-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-09-17 | — | — | US | claimed |
| WO-2009108551-A2 | HETEROARYL AMIDE ANALOGUES | H. LUNDBECK A/S (DK) | 2009-09-03 | — | — | WO | claimed |
| WO-2009023623-A1 | HETEROARYL AMIDE ANALOGUES | H, LUNDBECK A/S (DK) | 2009-02-19 | — | — | WO | claimed |
| EP-1948164-A1 | PHARMACEUTICAL COMPOSITIONS OF MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES, LTD. (IN) | 2008-07-30 | — | — | EP | claimed |
| EP-1907359-A2 | 3,5-SUBSTITUTED PIPERIDINE DERIVATIVES EFFECTIVE ON RENIN-RELATED DISORDERS | Novartis AG (CH) | 2008-04-09 | — | — | EP | claimed |
| WO-2007045979-A1 | PHARMACEUTICAL COMPOSITIONS OF MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-04-26 | — | — | WO | claimed |
| WO-2007006534-A2 | PIPERIDINE DERIVATIVES USEFUL IN THE DIAGNOSTIC AND THERAPEUTIC TREATMENT OF DISEASES DEPENDING ON RENIN ACTIVITY | NOVARTIS AG (CH) | 2007-01-18 | — | — | WO | claimed |
| EP-2439202-B1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | SALVAT LAB SA (ES) | 2016-04-20 | — | — | EP | disclosed |
| US-8822452-B2 | Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 | LABORATORIOS SALVAT, S.A. (ES) | 2014-09-02 | — | — | US | disclosed |
| US-20130303522-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2013-11-14 | — | — | US | disclosed |
| US-8524894-B2 | Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 | LABORATORIOS SALVAT, S.A. (ES) | 2013-09-03 | — | — | US | disclosed |
| US-20120190680-A1 | Heteroaryl Amide Analogues | H. LUNDBECK A/S (DK) | 2012-07-26 | — | — | US | disclosed |
| CN-1681784-A | Azabicyclo derivatives as muscarinic receptor antagonists | RANBAXY LAB LTD (IN) | 2005-10-12 | — | — | CN | disclosed |
| EP-1493739-A1 | Thiophene derivatives of aminoacids, process for the preparation thereof and compositions containing them | Warner-Lambert Company LLC (US) | 2005-01-05 | — | — | EP | disclosed |
| US-6245817-B1 | NEUROPEPTIDE Y | BAYER CORPORATION | 2001-06-12 | — | — | US | disclosed |
| US-6060484-A | Anti-viral method | ELI LILLY AND COMPANY (US) | 2000-05-09 | — | — | US | disclosed |
| WO-1997041846-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1997-11-13 | — | — | WO | disclosed |
| EP-0806205-A2 | Urea, thiourea and guanidine compounds and their use as anti-viral agents | ELI LILLY AND COMPANY (US) | 1997-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303522-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | MEN1 827/4885KMT2A 3868/4885HTR1E 749/4885 |
| US-20090233920-A1 | ORGANIC COMPOUNDS | REN, ACE, AGTR1 | MEN1 2386/4885KMT2A 3192/4885HTR1E 648/4885 |
| US-20120190680-A1 | Heteroaryl Amide Analogues | P2RX3, P2RX2, ADORA2A | MEN1 4875/4885KMT2A 2778/4885HTR1E 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.